:quality(85)//cloudfront-us-east-1.images.arcpublishing.com/infobae/CV2G2D2FTFCZHE2AP7O7GDP3AU.jpg "Cofepris has warned of the ineffectiveness of Octralin, a drug used in transplant patients")
The Federal Commission for Protection against Health Risks (Cofepris) on Tuesday ordered doctors not to supply or prescribe the drug Octralin, the substance tacrolimus, to their patients.
WHO commends Chamber of Deputies for regulating trans fats in food and drink
The project, which is just awaiting publication in the DOF, points out that the consumption of trans fatty acids significantly increases the risk of death from all causes.
And it is that this immunosuppressant from Laboratorios Raam de Sahuayo is provided to people who have undergone a liver, kidney and/or heart transplant to prevent organ rejection.
However, the agency assured in a statement that it has at least 56 reports in which a low concentration of tacrolimus in the blood is indicated, indicating its therapeutic ineffectiveness.
“Given the health risks of transplant patients, this health authority, in strict compliance with articles 397, 404 paragraphs X, XII and XIII and 414 of the general law on health, orders health professionals to no longer use or prescribe Octralin in its two presentations, 1.0 mg and 5.0 mg, until this health authority concludes the investigation”
In this regard, Cofepris has recommended to patients that in the event of treatment with tacrolimus from Laboratorios Raam de Sahuayo, they consult their doctor to seek therapeutic alternatives that do not endanger their health.
National Lottery: here are the winners of the Tris
Here are the results of the Tris Extra draw published by the Mexican lottery and find out if you were one of the winners
More information in development…